Contact Us
Drug Search Results
More Filters [+]

Cenicriviroc

Alternative Names: cenicriviroc, tbr-652
Latest Update: 2025-01-06
Latest Update Note: News Article

Product Description

Cenicriviroc (CVC) is a novel, orally administered, potent chemokine 2 and 5 receptor antagonist currently in development for the treatment of liver fibrosis in adults with NASH. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31881392/)

Mechanisms of Action: CCR2 Antagonist,CCR5 Antagonist,Immunomodulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Tobira
Company Location: SOUTH SAN FRANCISCO CA 94080
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cenicriviroc

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Hepatitis, Alcoholic|Liver Cirrhosis|Non-alcoholic Steatohepatitis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2016-004754-15

P2

Unknown status

Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis|Liver Cirrhosis

2027-06-05

Recent News Events

Date

Type

Title

01/06/2025

News Article

 Algernon Pharmaceuticals Receives Notice of Allowance from USPTO For Repirinast in Kidney Disease Patent

05/14/2024

PubMed

 CCR2/CCR5 antagonist cenicriviroc reduces colonic inflammation and fibrosis in experimental colitis.

04/21/2024

PubMed

 Cenicriviroc, a CCR2/CCR5 antagonist, promotes the generation of type 1 regulatory T cells.

03/28/2024

PubMed

 CC Chemokine Family Members' Modulation as a Novel Approach for Treating Central Nervous System and Peripheral Nervous System Injury-A Review of Clinical and Experimental Findings.

10/02/2023

News Article

 Non-Alcoholic Steatohepatitis (NASH) Drugs Market 2023 Global Demand and Emerging Trends by 2031

09/29/2023

News Article

 NASH Market Size 2023 with Company Profile, Sales, Revenue, Average Selling Price, Gross Margin and Forecast to 2032

09/13/2023

News Article

 Non-Alcoholic Steatohepatitis Market will Revenue to Cross USD 23874.61 million in2023 to 2030 (New Report) Research by Business, Top Companies report covers, new opportunities planning, and consumption by Regional data

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions